Showing results (301-310 of 329) with videos related to
Sort By:
Pageof 33
International Journal of Cardiology|March 7, 2018
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AFAdam S Barnett, Derek D Cyr, Shaun G Goodman, et al.American Heart Journal|August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY LibraryJohn L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.Journal of the American Heart Association|August 19, 2020
Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) TrialIda Gregersen, Annika E Michelsen, Ngoc Nguyen Lunde, et al.Heart Rhythm|May 17, 2014
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.European Heart Journal|August 24, 2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.Biorxiv : the Preprint Server for Biology|July 1, 2024
A Multi-Omics Approach to Defining Target Organ Injury in Youth with Primary HypertensionKalyani Ananthamohan, Tammy M Brady, Mohammed Arif, et al.Circulation|May 29, 2008
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery diseaseMark Y Chan, Mauricio G Cohen, Christopher K Dyke, et al.Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.Thrombosis and Haemostasis|January 10, 2014
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic SubstudyRobert F Storey, Jayaprakash Kotha, Susan S Smyth, et al.Journal of the American College of Cardiology|December 10, 2013
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)Shaun G Goodman, Daniel M Wojdyla, Jonathan P Piccini, et al.Pageof 33